Genesis MedTech has sold its JC Medical company to Edwards Lifesciences. This includes the intellectual property (IP) and commercial rights for the J-Valve transcatheter aortic valve replacement (TAVR) to treat severe aortic regurgitation.

Genesis MedTech已将其JC医疗公司出售给Edwards Lifesciences。这包括用于治疗严重主动脉瓣关闭不全的J瓣经导管主动脉瓣置换术（TAVR）的知识产权（IP）和商业权利。

Genesis still has the exclusive right to develop, manufacture, and commercialize the J-Valve system in China. In July 2023, the company finished patient enrollment for the J-Valve transfemoral system’s (J-Valve TF) clinical study to treat aortic regurgitation. The one-year patient follow-up was also recently completed..

Genesis仍然拥有在中国开发、制造和商业化J阀系统的专有权。2023年7月，该公司完成了J-Valve经股动脉系统（J-Valve TF）治疗主动脉瓣关闭不全的临床研究的患者登记。最近还完成了为期一年的患者随访。。

In August 2023, J-Valve TF was awarded breakthrough status by the U.S. Food and Drug Administration (FDA). Enrollment for its U.S. early feasibility study was finished in February 2024 and JC Medical earned FDA approval to begin J-Valve TF’s pivotal clinical trial in the first half of this year.

2023年8月，J-Valve TF被美国食品和药物管理局（FDA）授予突破性地位。美国早期可行性研究的报名工作于2024年2月完成，JC Medical获得FDA批准，于今年上半年开始J-Valve TF的关键临床试验。

Edwards also made a $25 million equity investment in Genesis MedTech. The funds will support its product and market development efforts, according to the company.

爱德华兹还对Genesis MedTech进行了2500万美元的股权投资。该公司表示，这些资金将支持其产品和市场开发工作。

'J-VALVE has unique advantages in treating aortic valve regurgitation.' said Warren Wang, chairman and CEO of Genesis MedTech Group. 'We hope that J-Valve can expand its global impact, enabling more patients to benefit from this innovative product. We will continue strengthening our focus on developing innovative products and explore better medical solutions to benefit more patients worldwide.'.

“J型瓣膜在治疗主动脉瓣返流方面具有独特的优势。”Genesis MedTech Group董事长兼首席执行官沃伦·王（WarrenWang）说我们希望J-Valve能够扩大其全球影响力，使更多患者受益于这种创新产品。。

Last month, Edwards announced two investments: one agreement to acquire JenaValve, and another to exercise the option to acquire Endotronix.

上个月，爱德华兹宣布了两项投资：一项协议收购JenaValve，另一项协议行使收购Endotronix的期权。